$MRKR
Marker Therapeutics, Inc. Stock $mrkr

$mrkr Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000119312516541539 Filed on April 14, 2016

Income Statement

Concept	2015	2014 Q4	2014
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.710M	$110.0K	$190.0K
YoY Change	800.0%	-85.71%	-90.5%
% of Gross Profit
Research & Development	$1.711M	$280.0K	$189.0K
YoY Change	805.38%	-36.36%	-71.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.711M	$390.0K	$189.0K
YoY Change	805.38%	-67.77%	-92.89%
Operating Profit	-$6.159M		-$3.371M
YoY Change	82.71%
Interest Expense	-$27.88M	-$300.0K	-$630.0K
YoY Change	4325.4%	-76.56%	215.0%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change			-100.0%
Pretax Income	-$34.07M	-$740.0K	-$30.88M
YoY Change	10.33%	-78.74%	458.41%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$34.07M	-$740.0K	-$30.88M
YoY Change	10.31%	-78.74%	458.46%
Net Earnings / Revenue
Basic Earnings Per Share	-$9.30
Diluted Earnings Per Share	-$9.30	-$404.4K	-$23.94M
COMMON SHARES
Basic Shares Outstanding	3.662M shares
Diluted Shares Outstanding	3.662M shares

Balance Sheet

Concept	2015	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.580M	$140.0K	$140.0K
YoY Change	4600.0%	180.0%	180.0%
Cash & Equivalents	$6.580M	$140.0K	$140.0K
Short-Term Investments
Other Short-Term Assets	$70.00K	$80.00K	$80.00K
YoY Change	-12.5%	166.67%	166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.650M	$224.4K	$220.0K
YoY Change	2922.73%	180.56%	175.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	-$4.448K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$6.650M	$224.4K	$220.0K
Total Long-Term Assets	$0.00	-$4.448K	$0.00
Total Assets	$6.650M	$220.0K	$220.0K
YoY Change	2922.73%	175.0%	175.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$970.0K	$620.0K	$620.0K
YoY Change	56.45%	-65.93%	-65.93%
Accrued Expenses		$70.00K	$70.00K
YoY Change		-97.0%	-97.0%
Deferred Revenue
YoY Change
Short-Term Debt	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	-98.56%	-98.56%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$28.01M	$1.248M	$1.250M
YoY Change	2140.8%	-85.9%	-85.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.01M	$1.248M	$1.250M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$28.01M	$1.250M	$1.250M
YoY Change	2140.8%	-85.88%	-85.88%
SHAREHOLDERS EQUITY
Retained Earnings		-$86.31M
YoY Change
Common Stock		$20.32K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.36M	-$1.024M	-$1.020M
YoY Change
Total Liabilities & Shareholders Equity	$6.650M	$224.4K	$220.0K
YoY Change	2922.73%	180.56%	175.0%

Cashflow Statement

Concept	2015	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$34.07M	-$740.0K	-$30.88M
YoY Change	10.31%	-78.74%	458.46%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$4.343M	-$670.0K	-$2.187M
YoY Change	98.59%	-1216.67%	216.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.326M		$1.878M
YoY Change	23.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.78M	200.0K	2.281M
YoY Change	372.62%	-1100.0%	221.2%
NET CHANGE
Cash From Operating Activities	-4.343M	-670.0K	-2.187M
Cash From Investing Activities
Cash From Financing Activities	10.78M	200.0K	2.281M
Net Change In Cash	6.435M	-470.0K	93.36K
YoY Change	6792.64%	-1275.0%	366.78%
FREE CASH FLOW
Cash From Operating Activities	-$4.343M	-$670.0K	-$2.187M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70990762	shares
CY2015Q1	tpiv	Number Of Common Stock Included In Unit Offering NumberOfCommonStockIncludedInUnitOffering	1	shares
CY2015Q2	dei	Entity Public Float EntityPublicFloat	36517000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-8768003
CY2013Q4	us-gaap	Cash Cash	48589
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20318815	shares
CY2014Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	20319
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2659417	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20318815	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	9415
CY2014Q4	us-gaap	Notes Payable NotesPayable	29942
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1248084
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12471000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-1023636
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85265776
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Before Tax1 AccumulatedOtherComprehensiveIncomeLossBeforeTax1	0
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	9000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	492365
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	9000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86309731
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	224448
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	693362
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	30000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10433000
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12471000
CY2014Q4	us-gaap	Cash Cash	141944
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2014Q4	us-gaap	Assets Current AssetsCurrent	224448
CY2014Q4	us-gaap	Loans And Leases Receivable Commercial LoansAndLeasesReceivableCommercial	-23000
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	82504
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	9000
CY2014Q4	tpiv	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.83
CY2014Q4	tpiv	Deferred Tax Stock Based Compensation DeferredTaxStockBasedCompensation	1871000
CY2014Q4	tpiv	Deferred Tax Technology Licensing Fee DeferredTaxTechnologyLicensingFee	167000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70550763	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	52106497	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70550763	shares
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10826000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	967358
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-21360356
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	112077520
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Before Tax1 AccumulatedOtherComprehensiveIncomeLossBeforeTax1	0
CY2015Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	26493000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	30000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8359000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	945000
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	26493000
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	492365
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	26493000
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	492000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133508427
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6645367
CY2015Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	70551
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Notes Payable NotesPayable	30000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28005723
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10826000
CY2015Q4	us-gaap	Cash Cash	6576564
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	4336000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2015Q4	us-gaap	Assets Current AssetsCurrent	6645367
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	24123000
CY2015Q4	us-gaap	Loans And Leases Receivable Commercial LoansAndLeasesReceivableCommercial	-23000
CY2015Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	68803
CY2015Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	26493000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	117000
CY2015Q4	tpiv	Number Of Warrants Issued NumberOfWarrantsIssued	86730975	shares
CY2015Q4	tpiv	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.74
CY2015Q4	tpiv	Deferred Tax Assets Operating Loss Carryforwards Reversal DeferredTaxAssetsOperatingLossCarryforwardsReversal	520000
CY2015Q4	tpiv	Deferred Tax Assets License Agreement DeferredTaxAssetsLicenseAgreement	268000
CY2015Q4	tpiv	Deferred Tax Stock Based Compensation DeferredTaxStockBasedCompensation	1897000
CY2015Q4	tpiv	Deferred Tax Technology Licensing Fee DeferredTaxTechnologyLicensingFee	185000
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	100	pure
CY2015Q1	tpiv	Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchase Agreement AggregatePurchasePriceOfSharesAgreedToPurchaseUnderStockPurchaseAgreement	950000
CY2015Q1	tpiv	Warrants Issued Finders Fee And Offering Costs WarrantsIssuedFindersFeeAndOfferingCosts	50000
CY2015Q1	tpiv	Equity Units Issued Price Per Unit EquityUnitsIssuedPricePerUnit	0.20
CY2015Q1	tpiv	Number Of Equity Units Issued NumberOfEquityUnitsIssued	5000000	shares
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.00
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2724847	shares
CY2014	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	65430	shares
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2187145
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15465213	shares
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-30883096
CY2014	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-30824762
CY2014	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	492296
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	581
CY2014	us-gaap	Profit Loss ProfitLoss	-30883096
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-3370927
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1265000
CY2014	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-9122000
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	58334
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-52976
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	67500
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26884231
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-58334
CY2014	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain	708000
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4116000
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	93355
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1391123
CY2014	us-gaap	Interest And Debt Expense InterestAndDebtExpense	83247
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	418000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	189000
CY2014	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	-15000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2280500
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1877500
CY2014	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	210000
CY2014	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	-58334
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-145199
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3181927
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10449000
CY2014	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	26884231
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	525000
CY2014	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-581
CY2014	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	42000
CY2014	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	2415000
CY2014	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	369000
CY2014	tpiv	Convertible Notes Promissory Notes Loan Payable Related Party Due To Related Parties And Accrued Interest Converted Into Series A And B Preferred Stock And Immediately Converted Into Common Stock Amount ConvertibleNotesPromissoryNotesLoanPayableRelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAAndBPreferredStockAndImmediatelyConvertedIntoCommonStockAmount	30951078
CY2014	tpiv	Conversion Of Accounts Payable To Common Stock Amount ConversionOfAccountsPayableToCommonStockAmount	4349428
CY2014	tpiv	Private Placement Amount PrivatePlacementAmount	1877500
CY2014	tpiv	Stock Based Compensation Amount StockBasedCompensationAmount	1391123
CY2014	tpiv	Accretion Of Interest On Convertible Debt AccretionOfInterestOnConvertibleDebt	492296
CY2014	tpiv	Common Stock Warrants Equity Treatment CommonStockWarrantsEquityTreatment	2556133	shares
CY2014	tpiv	Common Stock Warrants Liability Treatment CommonStockWarrantsLiabilityTreatment	103284	shares
CY2014	tpiv	Permanent Differences Other Permanent Differences PermanentDifferencesOtherPermanentDifferences	-62000
CY2014	tpiv	Class Of Warrant Or Right Outstanding Weighted Average Remaining Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife	P4Y1M24D
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="10%" align="left"><b>NOTE 1:</b></td> <td valign="top" align="left"><b>NATURE OF OPERATIONS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A Phase I study at the Mayo Clinic, Rochester, MN, evaluating the safety and immune responses of a set of proprietary HER2/neu+ antigens has been successfully completed and the results led to the decision to proceed with Phase II clinical studies in 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> A separate Phase I study has also been conducted at Mayo Foundation (“Mayo”) in Ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to Ovarian and Triple Negative Breast Cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications. This study has been successfully completed and the results led to the decision to proceed with multiple Phase II studies in 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In addition, enhancing the visibility of cancer or infected cells to a patient’s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune’s PolyStart nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient’s cancer cells.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at December 31, 2015, the Company had a working capital deficiency and has incurred significant losses since inception in the development of its business. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund clinical trials, ongoing research and development, maintenance and protection of patents, accommodation from certain debt obligations and ultimately on generating future profitable operations. Planned expenditures relating to current and future clinical trials of the Company’s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Management is addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation. Management’s plans are intended to return the Company to financial stability and improve continuing operations. The Company is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet immediate working capital requirements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Historically the Company has raised capital through issuances of various financial instruments and the Company recently completed significant restructuring of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company over the next twelve months.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> There is no certainty that the Company will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products to marketability.</p> </div>
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9Y29D
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0210	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55690647	shares
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001094038
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	3584150	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.30	pure
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4343397
CY2015	dei	Entity Registrant Name EntityRegistrantName	TAPIMMUNE INC.
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Prior Period Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Certain prior period amounts that were combined in the December 31, 2014 consolidated financial statements have been reclassified for comparability with the December 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.</p> </div>
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock based transactions, the fair value of the components of the derivative liabilities - warrants and accrued liabilities.</p> </div>
CY2015	dei	Trading Symbol TradingSymbol	TPIV
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43947067	shares
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M10D
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-34066390
CY2015	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-34066390
CY2015	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-27872585
CY2015	us-gaap	Profit Loss ProfitLoss	-34066390
CY2015	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-24697
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-6158958
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	16835000
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1645000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	775
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-13701
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-9313000
CY2015	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	27873000
CY2015	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	6434620
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1705067
CY2015	us-gaap	Interest And Debt Expense InterestAndDebtExpense	10925
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	191000
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9219998
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1711177
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	346000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10778017
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2326015
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	96018
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4447781
CY2015	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	16835000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11582000
CY2015	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	27872585
CY2015	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	22000
CY2015	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	1600000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-199000
CY2015	tpiv	Tax Credit Carryforward Expiration Year Range Start TaxCreditCarryforwardExpirationYearRangeStart	2029
CY2015	tpiv	Tax Credit Carryforward Expiration Year Range End TaxCreditCarryforwardExpirationYearRangeEnd	2035
CY2015	tpiv	Number Of Warrants Exercised NumberOfWarrantsExercised	37079990	shares
CY2015	tpiv	Income Tax Reconciliation Tax Write Off Of Net Operating Losses IncomeTaxReconciliationTaxWriteOffOfNetOperatingLosses	3591000
CY2015	tpiv	Private Placement Amount PrivatePlacementAmount	2326015
CY2015	tpiv	Stock Based Compensation Amount StockBasedCompensationAmount	1514266
CY2015	tpiv	Shares Issued In Settlement Agreement Amount SharesIssuedInSettlementAgreementAmount	26473
CY2015	tpiv	Exercise Of Warrants Amount ExerciseOfWarrantsAmount	9219998
CY2015	tpiv	Number Of Ovarian Cancer Patients NumberOfOvarianCancerPatients	30000	Patient
CY2015	tpiv	Percentage Of Breast Cancers PercentageOfBreastCancers	0.50	pure
CY2015	tpiv	Percentage Of Ovarian Cancers PercentageOfOvarianCancers	0.95	pure
CY2015	tpiv	Common Stock Warrants Equity Treatment CommonStockWarrantsEquityTreatment	2548632	shares
CY2015	tpiv	Common Stock Warrants Liability Treatment CommonStockWarrantsLiabilityTreatment	49557865	shares
CY2015	tpiv	Loss On Settlement Agreement LossOnSettlementAgreement	24697
CY2015	tpiv	Valuation Methodology ValuationMethodology	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the years ended 2015 and 2014 is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="17%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="17%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; WIDTH: 87.95pt"> <b>Stock Purchase Warrants</b></p> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Weighted Average Inputs for the Period</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; WIDTH: 58.6pt"> <b>Date of valuation</b></p> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For the Year<br /> Ending December 31,<br /> 2015</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>For the Year<br /> Ending December 31,<br /> 2014</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Strike price</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.70</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Volatility (annual)</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">166</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Risk-free rate</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.00</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Contractual term (years)</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2. 25</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Dividend yield (per share)</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>
CY2015	tpiv	Financial Assets And Liabilities Measured At Fair Value On Recurring Basis FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>As of December 31, 2015</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>Fair Value Measurements</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Fair Value</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> <b>Level 1</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> <b>Level 2</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Level 3</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Derivative liability - warrants</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>As of December 31, 2014</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="18" align="center"><b>Fair Value Measurements</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Carrying<br /> Value</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> <b>Level 1</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> <b>Level 2</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Level 3</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"><b>Total</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Derivative liability - warrants</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">          9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">          9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">          9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> </table> </div>
CY2015	tpiv	Measured At Fair Value MeasuredAtFairValue	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2015:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="19%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> <b>Derivative liability – warrants</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance – December 31, 2014</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Additions during the period</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,446,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Settlement of debt</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16,835,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Change in fair value of warrant liability</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,873,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Balance – December 31, 2015</p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,493,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> </table> </div>
CY2015	tpiv	Income Tax Reconciliation Change In Fair Value Of Derivative Liability IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability	9477000
CY2015	tpiv	Permanent Differences Other Permanent Differences PermanentDifferencesOtherPermanentDifferences	-12000
CY2015	tpiv	Number Of Warrants Extinguished Or Expired NumberOfWarrantsExtinguishedOrExpired	203905	shares
CY2015	tpiv	Class Of Warrant Or Right Outstanding Issued Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingIssuedWeightedAverageExercisePrice	0.54
CY2015	tpiv	Class Of Warrant Or Right Outstanding Exercised Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingExercisedWeightedAverageExercisePrice	0.25
CY2015	tpiv	Class Of Warrant Or Right Outstanding Extinguished Or Expired Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingExtinguishedOrExpiredWeightedAverageExercisePrice	2.39
CY2015	tpiv	Class Of Warrant Or Right Outstanding Weighted Average Remaining Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife	P4Y2M27D
CY2015	tpiv	Class Of Warrant Or Right Outstanding Issued Weighted Average Remaining Life ClassOfWarrantOrRightOutstandingIssuedWeightedAverageRemainingLife	P4Y3M18D
CY2015	tpiv	Additions During Year AdditionsDuringYear	15446000
CY2015	tpiv	Accounts Payable Settled In Amount AccountsPayableSettledInAmount	21913
CY2015	tpiv	Adjustments To Additional Paid In Capital Finders Fee On Warrants Exercised AdjustmentsToAdditionalPaidInCapitalFindersFeeOnWarrantsExercised	767995
CY2015	tpiv	Finders Fee On Exercise Of Warrants FindersFeeOnExerciseOfWarrants	767996
CY2015	tpiv	Noncash Or Part Noncash Transaction Fair Value Of Warrants Issued NoncashOrPartNoncashTransactionFairValueOfWarrantsIssued	9313000
CY2015	tpiv	Noncash Or Part Noncash Transaction Issuance Of Additional Warrants NoncashOrPartNoncashTransactionIssuanceOfAdditionalWarrants	6133000
CY2015	tpiv	Noncash Or Part Noncash Transaction Reclassification Of Warrant Liabilities To Equity NoncashOrPartNoncashTransactionReclassificationOfWarrantLiabilitiesToEquity	16835000
CY2015	tpiv	Fair Value Of Additional Warrants Issued FairValueOfAdditionalWarrantsIssued	6133000

Files In Submission

Name	View Source	Status
0001193125-16-541539-index-headers.html	Edgar Link	pending
0001193125-16-541539-index.html	Edgar Link	pending
0001193125-16-541539.txt	Edgar Link	pending
0001193125-16-541539-xbrl.zip	Edgar Link	pending
d106912d10k.htm	Edgar Link	pending
d106912dex311.htm	Edgar Link	pending
d106912dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpiv-20151231.xml	Edgar Link	completed
tpiv-20151231.xsd	Edgar Link	pending
tpiv-20151231_cal.xml	Edgar Link	unprocessable
tpiv-20151231_def.xml	Edgar Link	unprocessable
tpiv-20151231_lab.xml	Edgar Link	unprocessable
tpiv-20151231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRKR
Marker Therapeutics, Inc. Stock $mrkr

2015 Form 10-K Financial Statement

#000119312516541539 Filed on April 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRKR Marker Therapeutics, Inc. Stock $mrkr

2015 Form 10-K Financial Statement

#000119312516541539 Filed on April 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRKR
Marker Therapeutics, Inc. Stock $mrkr